Wikipedia -WSS

Wikipedia

author：fashion 2025-10-01 02:44:27 - browse：17

Dozens of sickle cells in a whirlpool — coverage from STAT — Adobe

Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes.

The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?

“We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Ebola: Gilead Sciences antiviral shows promise as new treatment

WSS

Patients' immediate access to test results puts radiologists in a bind

Male and female sex labels in research insufficient, scientists say

Steward Health Care Massachusetts hospitals face fiscal disaster

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Americans' trust in science, scientist continues decline: Report

focus

Wikipedia

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Trump demands the U.S. pay no more for drugs than other countries … again

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: CAR

Anesthesiologist group: stop taking Ozempic before surgery

Boston's new lab space is opening empty

focus

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

HHS secretary Becerra pressed on Change HealthCare cyberattack

Pfizer plans to depart BIO

Why scientists need input from humanists on sensitive research

UCLA team creates talking throat patch for voice disorders

entertainment

hotspot

focus

focus